Skip to main content

nelarabine

Generic: NELARABINE·Brand: ARRANON, Arranon, NELARABINE

nelarabine: sourced relationships with 1 company · 3 clinical trials tracked · 1 FDA decision.

nelarabine evidence translation

What we can confirm

1 FDA record · 3 tracked trials

What it means

Source-backed records connect nelarabine to NEXS; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could nelarabine → NEXS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
NEXUS BIOPHARMA INC (NEXS)
Reported 2023-06-02 · Current development: unknownSource
Approved
NEXUS BIOPHARMA INC (NEXS)
Reported 2023-06-02 · Current development: unknownSource
Approved
Clinical Trial Registry Records (3)

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

NCT07072585Registry updated 2026-07-30·Phase 2/Phase 3
Not yet recruiting

Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)

InterventionalRandomizedopen1,708 targetStarted 2026-08Completion 2035-09Children's Oncology Group

SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319Registry updated 2026-08-10·Phase 2
Recruiting

Primary endpoint: Minimal residual disease (MRD)-negativity rate in patients with T cell acute lymphoblastic leukemia

Interventionalopen100 targetStarted 2024-12Completion 2033-124 sites · United StatesSt. Jude Children's Research Hospital

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751Registry updated 2026-06-17·Phase 2/Phase 3
Active, not recruiting

Primary endpoint: Event-free survival of ALL patients (EFS)

InterventionalRandomizedsingle790 targetStarted 2017-03Completion 2028-098 sites · Australia, United StatesSt. Jude Children's Research Hospital
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphom(NEXS)FDA ↗
ANDA215057UNKNOWNStandardIntravenousInjectable

Frequently asked questions

Which companies have sourced relationships with nelarabine?

nelarabine has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.

How many clinical trials involve nelarabine?

BioSniper tracks 3 clinical trials involving nelarabine.

What is nelarabine's latest FDA decision?

The most recent tracked FDA decision for nelarabine is Approval for 1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphom, dated June 2, 2023.